|
|
|
| Progress in the diagnosis and treatment of lower-risk myelodysplastic syndrome |
| DING Yubin1 TANG Yufeng2 TANG Xudong3 |
1.Graduate School, China Academy of Chinese Medical Sciences, Beijing 100700, China;
2.Department of Laboratory, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China;
3.Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China |
|
|
|
Abstract The lower-risk myelodysplastic syndrome (MDS) is defined by the prognostic scoring system, and the inclusion of molecular abnormalities is conducive to the accuracy of risk stratification of the system. In view of the peripheral blood cytopenia of lower-risk MDS, erythropoietin analogues (erythropoiesis-stimulating agents, darbepoetin-α), transforming growth factor-β (TGF-β) pathway blockers (luspatercept) and Lenalidomide can be selected to improve the anemia of MDS, Romiplostim and Eltrombopag are used for thrombocytopenia, demethylation drugs and antithymocyte globulin ameliorate pancytopenia of MDS, and many new drugs in clinical trials are intended for the signaling pathway of specific gene mutation. In this paper, the diagnosis and treatment of low-risk MDS are reviewed in order to guide the clinical treatment.
|
|
|
|
|
|
[1] Sekeres MA，Patel BJ. Lowering the boom on lower-risk myelodysplastic syndromes [J]. Hematology Am Soc Hematol Educ Program，2019，2019（1）：367-372.
[2] Makishima H，Yoshizato T，Yoshida K，et al. Dynamics of clonal evolution in myelodysplastic syndromes [J]. Nat Genet，2017，49（2）：204-212.
[3] Haferlach T，Nagata Y，Grossmann V，et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes [J]. Leukemia，2014，28（2）：241-247.
[4] Greenberg PL，Tuechler H，Schanz J，et al. Revised international prognostic scoring system for myelodysplastic syndromes [J]. Blood，2012，120（12）：2454-2465.
[5] Nazha A，Al-Issa K，Hamilton BK，et al. Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes [J]. Leukemia，2017，31（12）：2848-2850.
[6] Nazha A，Komrokji RS，Meggendorfer M，et al. A personalized prediction model to risk stratify patients with myelodysplastic syndromes [J]. Blood，2018，132（suppl 1）：793.
[7] Bejar R，Stevenson K，Abdel-Wahab O，et al. Clinical effect of point mutations in myelodysplastic syndromes [J]. N Engl J Med，2011，364（26）：2496-2506.
[8] Platzbecker U，Fenaux P，Ades L，et al. Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials [J]. Blood，2019， 133（10）：1020-1030.
[9] 韩冰，李红敏，陈芳菲，等.骨髓增生异常综合征贫血原因及治疗策略[J].天津医药，2018，46（8）：794-798.
[10] Platzbecker U，Symeonidis A，Oliva EN，et al. A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes [J]. Leukemia，2017，31（9）：1944-1950.
[11] Platzbecker U，Germing U，G?觟tze KS，et al. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes（PACE-MDS）：a multicentre，open-label phase 2 dose-finding study with long-term extension study [J]. Lancet Oncol，2017，18（10）：1338-1347.
[12] Fenaux P，Platzbecker U，Mufti GJ，et al. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes [J]. N Engl J Med，2020，382（2）：140-151.
[13] Schanz J，Tuchler H，Sole F，et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes（MDS）and oligoblastic acute myeloid leukemia after MDS derived from an international database merge [J]. J Clin Oncol，2012，30（8）：820-829.
[14] List A，Dewald G，Bennett J，et al. Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the my-elodysplastic syndrome with chromosome 5q deletion [J]. N Engl J Med，2006，355（14）：1456-1465.
[15] List AF，Bennett JM，Sekeres MA，et al. Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del（5q）MDS [J]. Leukemia，2015，29（12）：2452.
[16] Fenaux P，Giagounidis A，Selleslag D，et al. MDS-004 Lenalidomide del5q Study Group. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate1-risk myelodysplastic syndromes with del5q [J]. Blood，2011， 118（14）：3765-3776.
[17] Sekeres MA，Swern AS，Giagounidis A，et al. The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del（5q）[J]. Blood Cancer J，2018，8（10）：90.
[18] Santini V，Almeida A，Giagounidis A，et al. Randomized phase Ⅲ study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del（5q）myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents [J]. J Clin Oncol，2016，34（25）：2988-2996.
[19] Giagounidis A，Mufti GJ，Fenaux P，et al. Results of a randomized，double-blind study of romiplostim versus placebo in patients with low/ intermediate-1-risk myelodysplastic syndrome and thrombocytopenia [J]. Cancer，2014， 120（12）：1838-1846.
[20] Oliva EN，Alati C，Santini V，et al. Eltrombopag versus placebo for lowrisk myelodysplastic syndromes with thrombocytopenia（EQoL-MDS）：phase 1 results of a single-blind，randomised，controlled，phase 2 superiority trial [J]. Lancet Haematol，2017，4（3）：e127-e136.
[21] Garcia-Manero G，Jabbour E，Borthakur G，et al. Randomized open-label phase Ⅱ study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes [J]. J Clin Oncol，2013，31（20）：2548-2553.
[22] Saunthararajah Y，Sekeres M，Advani A，et al. Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes [J]. J Clin Invest，2015， 125（3）：1043-1055.
[23] Jabbour E，Short NJ，Montalban-Bravo G，et al. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN [J]. Blood，2017，130（13）：1514-1522.
[24] Passweg JR，Giagounidis AA，Simcock M，et al. Immunosuppressive therapy for patients with myelodysplastic syndrome：a prospective randomized multicenter phase Ⅲ trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99 [J]. J Clin Oncol，2011，29（3）：303-309.
[25] Komrokji RS，Mailloux AW，Chen DT，et al. A phase Ⅱ multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction [J]. Haematologica，2014，99（7）：1176-1183.
[26] Sulser P，Pickel C，Günter J，et al. HIF hydroxylase inhibitors decrease cellular oxygen consumption depending on their selectivity [J]. FASEB J，2020，34（2）：2344-2358.
[27] Saudan P，De Seigneux S，Hadaya K. Nephrology：what′s new in 2019? [J]. Rev Med Suisse，2020，16（676-7）：63-67.
[28] Voit RA，Sankaran VG. Stabilizing HIF to Ameliorate Anemia [J]. Cell，2020，180（1）：6.
[29] Kaplan J. Roxadustat and Anemia of Chronic Kidney Disease [J]. N Engl J Med，2019，381（11）：1070-1072.
[30] Kubasch AS，Platzbecker U. Setting Fire to ESA and EMA Resistance：New Targeted Treatment Options in Lower Risk Myelodysplastic Syndromes [J]. Int J Mol Sci，2019， 20（16）：3853.
[31] Buonamici S，Yoshimi A，Thomas M，et al. H3B-8800，an orally bioavailable modulator of the SF3b complex，shows efficacy in spliceosomemutant myeloid malignancies [J]. Blood，2016，128（22）：966.
[32] Lambert JM，Gorzov P，Veprintsev DB，et al. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain [J]. Cancer Cell，2009，15（5）：376-388.
[33] Sallman DA，DeZern AE，Steensma DP，et al. Phase 1b/2 combination study of APR-246 and azacitidine（AZA）in patients with TP53 mutant myelodysplastic syndromes（MDS）and acute myeloid leukemia（AML）[J]. Blood，2018，132（suppl 1）：3091.
[34] Buckstein RJ. Integrating patient-centered factors in the risk assessment of MDS [J]. Hematology Am Soc Hematol Educ Program，2019，2019（1）：373-380. |
|
|
|
